Last reviewed · How we verify

NCT05965037

The FLUYDO NC Post Market Clinical Follow-up Study

Completed Last updated 13 May 2024
What this trial tests

trial testing FLUYDO NC percutaneous transluminal coronary angioplasty balloon catheter in Coronary Artery Disease in 100 participants. Completed in 15 June 2023.

Timeline
1 November 2022
Primary endpoint
15 June 2023
15 June 2023

Quick facts

Lead sponsorAlvimedica
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 November 2022
Primary completion15 June 2023
Estimated completion15 June 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Alvimedica

Who can join

18 and older, any sex, with Coronary Artery Disease or Coronary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present observational study is to collect clinical data on the medical device non-implantable medical device Fluydo NC: coronary angioplasty non-compliant balloon dilatation catheter in the daily use in a not selected population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Alvimedica trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05965037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing